Anika Therapeutics Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2012
January 22, 2013 at 08:04 pm IST
Share
Anika Therapeutics Inc. provided earnings guidance for the fourth quarter and full year ended December 31, 2012. For the period, the company expects total revenue in the range of $22.0 million to $23.0 million, compared with $18.4 million in the fourth quarter of 2011.
For the full year, the company expects total revenue to be in the range of $70.0 million and $71.6 million, compared with $64.8 million a year earlier. The company expects to equal or exceed its previously announced guidance of $0.74 net income per diluted share for full-year 2012.
Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.